Beta
Bempedoic Acid
medicationATP citrate lyase inhibitor (brand name: Nexletol) for cholesterol reduction. Alternative for those who can't tolerate statins (no muscle pain side effects).
Reported Benefits
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Ray KK, et al.
In 779 high-risk patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia on maximally tolerated statins, bempedoic acid 180 mg daily reduced LDL-C by 15.1% at 12 weeks compared to a 2.4% increase with placebo.
Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials: A Meta-Analysis
Cicero AFG, et al.
Meta-analysis of 4 trials with 17,324 patients showed bempedoic acid reduced major adverse cardiovascular events by 12%, myocardial infarction by 24%, and revascularization by 18%, with mean LDL-C reduction of 26 mg/dL.
Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR Outcomes)
Nissen SE, et al.
In 13,970 statin-intolerant patients with or at high risk for cardiovascular disease, bempedoic acid reduced four-component major adverse cardiovascular events by 13% (11.7% vs 13.3%) and LDL-C compared to placebo.
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Ray KK, et al.
In 779 high-risk patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia on maximally tolerated statins, bempedoic acid 180 mg daily reduced LDL-C by 15.1% at 12 weeks compared to a 2.4% increase with placebo.
Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials: A Meta-Analysis
Cicero AFG, et al.
Meta-analysis of 4 trials with 17,324 patients showed bempedoic acid reduced major adverse cardiovascular events by 12%, myocardial infarction by 24%, and revascularization by 18%, with mean LDL-C reduction of 26 mg/dL.
Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR Outcomes)
Nissen SE, et al.
In 13,970 statin-intolerant patients with or at high risk for cardiovascular disease, bempedoic acid reduced four-component major adverse cardiovascular events by 13% (11.7% vs 13.3%) and LDL-C compared to placebo.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Elevated LDL cholesterol or total cholesterol levels
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Ray KK, et al.
In 779 high-risk patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia on maximally tolerated statins, bempedoic acid 180 mg daily reduced LDL-C by 15.1% at 12 weeks compared to a 2.4% increase with placebo.
Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials: A Meta-Analysis
Cicero AFG, et al.
Meta-analysis of 4 trials with 17,324 patients showed bempedoic acid reduced major adverse cardiovascular events by 12%, myocardial infarction by 24%, and revascularization by 18%, with mean LDL-C reduction of 26 mg/dL.
Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR Outcomes)
Nissen SE, et al.
In 13,970 statin-intolerant patients with or at high risk for cardiovascular disease, bempedoic acid reduced four-component major adverse cardiovascular events by 13% (11.7% vs 13.3%) and LDL-C compared to placebo.
Research (3 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!